title: Synthetic thymic fraction 5: effects of high dose administration on circulating lymphocytes in patients.
abstract: The synthetic pentapeptide (Arg-Lys-Asp-Val-Tyr; TP-5) corresponding to the active site of the hormone thymopoietin, was given at the dose of 300 mg/m2/day (1 day), higher than the usually administered, to a group of 27 immunodepressed patients in order to determine the tolerability and the immunomodulatory activity. The examination of a series of hematological parameters including counts of differential clustering of lymphocytes by cytofluorimetric analysis was performed 24 hr and 48 hr after treatment, and repeated at different intervals up to 14 days after treatment. TP-5 caused a significant increase of circulating lymphocytes and particularly of CD3+CD4+ and CD3+CD8+ subtypes, peaking at 48 hr and maintaining the increased values up to the last examination on day 14 from treatment. A faster increase (zenith at 24 hr) was observed for CD4+ cells, in comparison with CD8+ cells (zenith at 48 hr). The number of patients that increased total lymphocytes or lymphocyte subset after treatment ranged between 52.6 (CD4+ cells) and 69.2% (NK cells), whereas about 7.7% (NK cells) to 36.9% (CD4+ cells) remained unchanged and a smaller amount of 10.5% (CD4+ and CD8+ cells) or 23.1% (NK cells) showed a decrease greater than 10% of their respective basal value. No significant relationship between responders and non-responders can be found on the basis of previous treatments, cancer type, sex or age.
authors.affiliation: Medical Oncology Division, General Hospital, Udine, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Cartei
authors.forename: G
authors.initials: G
authors.lastname: Sava
authors.forename: G
authors.initials: G
authors.lastname: Salerno
authors.forename: A
authors.initials: A
authors.lastname: Bergamo
authors.forename: F
authors.initials: F
authors.lastname: Cartei
authors.forename: M
authors.initials: M
authors.lastname: Sanzari
authors.forename: P G
authors.initials: PG
authors.lastname: Sala
authors.forename: E
authors.initials: E
authors.lastname: Vigevani
authors.forename: G
authors.initials: G
authors.lastname: Tabaro
authors.forename: L
authors.initials: L
authors.lastname: Clocchiatti
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D016516:CD4-CD8 Ratio / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology; D011446:Prospective Studies; D013601:T-Lymphocytes / Q000187:drug effects*; D016305:Thymopentin / Q000627:therapeutic use*
chemical_list: D000276:Adjuvants, Immunologic; D016305:Thymopentin